Bioequivalence Trials with the Incomplet
โ
Nam-Kyoo Lim; Sang-Gue Park; Ed Stanek
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 107 KB
In bioequivalence trials, one often considers two or more generic products with the original one. The 3 x 3 crossover design can be adopted to evaluate the two generic candidates with a brand name drug, rather than conducting two separate 2 x 2 crossover trials. Dropouts, however, are more likely to